Indication intelligence, analysis and sector perception

Pluristem (PSTI) using stock as the collateral payments distorts your progress

September 18, 2017 1:11pm

After a hyped release, resorting to compensating “pushers” to drive momentum is injudicious in this climate ...

The PSTI news today has been the granting of a Fast Track Designation to the firm’s ongoing late-stage study of PLX-PAD cells for the treatment of Critical Limb Ischemia (CLI) in patients ineligible for revascularization by the U.S. FDA. With Fast Track Designation, there is an … increased possibility <KEY WORD: possibility> for a priority review by the FDA of PLX-PAD cells for the treatment of CLI – a little TO SUGESTIVE or way TOO early to ASSUME!

Get the message out within the confines of best practices!

BIOTECHSTOCKS.com is owned by MIDAM VENTURES LLC., a Florida Corporation has been compensated eleven thousand shares (11,000 shares, that’s $15,840 at today’s price $1.44) of PSTI’s stock – disclosed on 9/18/17. Didn’t the SEC just file a number of complaints, fines and a censure for these “dealings”? Real news, overstated press releases, fake news, hyped news – PSTI has a “history” of these dealings! SEC, where are you …?

The stock is trading up at $0.10 at $1.44 and already dropping from a morning high of $1.60 … WONDER ... WHY?

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

10 hours 12 min ago
RegMed Investors’ (RMi) pre-open: market, market and the sector pullbacks are driven by Israel retaliation against Iran tempered expectations for a rate cut

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.